Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review

被引：25
作者：
Blayney, Douglas W. [1 ,3 ]
Schwartzberg, Lee [2 ]
机构：
[1] Stanford Canc Inst, Stanford, CA 75216 USA
[2] Univ Nevada, Renown Inst Canc, Reno, NV USA
[3] 875 Blake Wilbur Dr,Room CC-2219,M-C 6576, Stanford, CA 94305 USA
来源：
CANCER TREATMENT REVIEWS | 2022年 / 109卷
关键词：
Chemotherapy -induced neutropenia; G-CSF; Trilaciclib; Plinablin; Efbemalenograstim alpha; Eflapegrastim; INDUCED FEBRILE NEUTROPENIA; COLONY-STIMULATING FACTOR; RELATIVE DOSE INTENSITY; PER-CYCLE PEGFILGRASTIM; US CLINICAL-PRACTICE; BREAST-CANCER; PRIMARY PROPHYLAXIS; PLINABULIN PLIN; BIOSIMILAR FILGRASTIM; RECEIVING CHOP;
D O I：
10.1016/j.ctrv.2022.102427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：10
相关论文
共 50 条
  • [31] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study)
    Wolff, Thomas
    Schulz, Holger
    Losem, Christoph
    Reichert, Dietmar
    Hurtz, Hans-Juergen
    Sandner, Reiner
    Harde, Johanna
    Grebhardt, Sina
    Potthoff, Karin
    Mueller, Udo
    Fietz, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 174 - 181
  • [32] The importance of prophylactic management of chemotherapy-induced neutropenia
    Repetto, L
    Accettura, C
    ANTI-CANCER DRUGS, 2003, 14 (09) : 725 - 730
  • [33] MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis
    Gascon, Pere
    Krendyukov, Andriy
    Hoebel, Nadja
    Aapro, Matti
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (03) : 241 - 246
  • [34] The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia
    Ouyang, Wen
    Liu, Yu
    Deng, Di
    Zhou, Fuxiang
    Xie, Conghua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S565 - S570
  • [35] Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia
    Fontanella, Caterina
    Bolzonello, Silvia
    Lederer, Bianca
    Aprile, Giuseppe
    BREAST CARE, 2014, 9 (04) : 239 - 245
  • [36] Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
    Aapro, Matti
    Boccia, Ralph
    Leonard, Robert
    Camps, Carlos
    Campone, Mario
    Choquet, Sylvain
    Danova, Marco
    Glaspy, John
    Hus, Iwona
    Link, Hartmut
    Sliwa, Thamer
    Tesch, Hans
    Valero, Vicente
    SUPPORTIVE CARE IN CANCER, 2017, 25 (11) : 3295 - 3304
  • [37] Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings
    Ibrahim, Eiman Y.
    Ehrlich, Barbara E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [38] Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
    Kamioner, Didier
    Fruehauf, Stefan
    Maloisel, Frederic
    Cals, Laurent
    Lepretre, Stephane
    Berthou, Christian
    BMC CANCER, 2013, 13
  • [39] Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns
    Tesch, Hans
    Ulshoefer, Thomas
    Vehling-Kaiser, Ursula
    Ottillinger, Bertram
    Bulenda, Dietmar
    Turner, Matthew
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (04) : 146 - 152
  • [40] Chemotherapy-induced neutropenia in lung cancer patients: The role of antibiotic prophylaxis
    Kouranos, Vasileios
    Dimopoulos, George
    Vassias, Antonios
    Syrigos, Kostas N.
    CANCER LETTERS, 2011, 313 (01) : 9 - 14
12345